EP 3119762 A1 20170125 - BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER
Title (en)
BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER
Title (de)
BENZIMIDAZOLDERIVATE ALS ERBB-TYROSINKINASEHEMMER ZUR BEHANDLUNG VON KREBS
Title (fr)
DÉRIVÉS DE BENZIMIDAZOLE EN TANT QU'INHIBITEURS DE LA TYROSINE KINASE ERBB POUR LE TRAITEMENT DU CANCER
Publication
Application
Priority
- US 201461968225 P 20140320
- US 2015021455 W 20150319
Abstract (en)
[origin: WO2015143148A1] Provided herein are benzimidazole derivatives, for example, of Formula I, and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a proliferative disease.
IPC 8 full level
C07D 401/14 (2006.01); A61K 31/55 (2006.01); A61P 35/00 (2006.01); C07D 403/04 (2006.01); C07D 403/14 (2006.01); C07D 405/14 (2006.01); C07D 409/14 (2006.01)
CPC (source: EP IL KR RU US)
A61K 31/4184 (2013.01 - RU); A61K 31/55 (2013.01 - IL KR RU US); A61P 35/00 (2018.01 - EP IL KR RU); A61P 43/00 (2018.01 - EP); C07D 223/04 (2013.01 - EP US); C07D 401/14 (2013.01 - EP IL KR RU US); C07D 403/04 (2013.01 - EP RU US); C07D 403/12 (2013.01 - EP US); C07D 403/14 (2013.01 - EP RU US); C07D 405/14 (2013.01 - EP IL KR RU US); C07D 409/14 (2013.01 - EP IL KR RU US)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
DOCDB simple family (publication)
WO 2015143148 A1 20150924; AU 2015231202 A1 20161006; AU 2015231202 B2 20190822; AU 2015231202 B9 20191024; CA 2943220 A1 20150924; CA 2943220 C 20240116; CA 3175724 A1 20150924; CA 3175724 C 20240109; CN 106536506 A 20170322; CN 114940673 A 20220826; CN 114989140 A 20220902; DK 3119762 T3 20210830; EP 3119762 A1 20170125; EP 3119762 B1 20210526; EP 3119762 B9 20211020; EP 3922630 A1 20211215; ES 2891734 T3 20220131; IL 247852 A0 20161130; IL 247852 B 20210429; IL 282651 A 20210630; IL 282651 B 20220401; IL 291000 A 20220501; IL 291000 B1 20231201; IL 291000 B2 20240401; JP 2017512833 A 20170525; JP 2020007327 A 20200116; JP 2022106967 A 20220720; JP 6577012 B2 20190918; JP 7073316 B2 20220523; JP 7394168 B2 20231207; KR 102416358 B1 20220707; KR 102663309 B1 20240503; KR 20170004968 A 20170111; KR 20220100081 A 20220714; KR 20240064750 A 20240513; MX 2016012097 A 20170427; MX 2020012165 A 20210129; NZ 724372 A 20210625; PT 3119762 T 20210831; RU 2016141052 A 20180426; RU 2016141052 A3 20181030; RU 2021101430 A 20210316; RU 2741914 C2 20210129; SG 11201607706S A 20161028; TW 201620896 A 20160616; TW 202028189 A 20200801; TW I683813 B 20200201; TW I807150 B 20230701; US 10005765 B2 20180626; US 10647707 B2 20200512; US 11787788 B2 20231017; US 2017183330 A1 20170629; US 2018291012 A1 20181011; US 2020291007 A1 20200917
DOCDB simple family (application)
US 2015021455 W 20150319; AU 2015231202 A 20150319; CA 2943220 A 20150319; CA 3175724 A 20150319; CN 201580023803 A 20150319; CN 202210345286 A 20150319; CN 202210345304 A 20150319; DK 15717994 T 20150319; EP 15717994 A 20150319; EP 21173958 A 20150319; ES 15717994 T 20150319; IL 24785216 A 20160915; IL 28265121 A 20210426; IL 29100022 A 20220228; JP 2017501110 A 20150319; JP 2019151001 A 20190821; JP 2022078150 A 20220511; KR 20167028920 A 20150319; KR 20227022282 A 20150319; KR 20247014448 A 20150319; MX 2016012097 A 20150319; MX 2020012165 A 20160919; NZ 72437215 A 20150319; PT 15717994 T 20150319; RU 2016141052 A 20150319; RU 2021101430 A 20150319; SG 11201607706S A 20150319; TW 104108911 A 20150319; TW 108147560 A 20150319; US 201515126997 A 20150319; US 201816005490 A 20180611; US 202016867451 A 20200505